Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Combo PharmaASX:S66 35 Receivables Turnover is 5.11 as of Dec. 2025. GuruFocus rates ASX:S66 with a GF Score™ of 35/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,944 Consumer Packaged Goods companies, Star Combo Pharma ranks better than 56.94% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Star Combo Pharma's Revenue for the
six
months ended in Dec. 2025 was A$11.93 Mil. Star Combo Pharma's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$2.33 Mil.
Hence, Star Combo Pharma's Receivables Turnover for the
six
months ended in Dec. 2025 was 5.11.
Star Combo Pharma (ASX:S66) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Star Combo Pharma Receivables Turnover Related Terms
Star Combo Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Star Combo Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:S66 vs PG, CL, KVUE: Receivables Turnover Comparison
For the Household & Personal Products subindustry, Star Combo Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Combo Pharma Receivables Turnover vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Star Combo Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Combo Pharma (ASX:S66) has a Receivables Turnover of 5.11 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Star Combo Pharma and its competitors. According to the industry distribution chart, Star Combo Pharma ranks #837 out of 1944 companies in the Consumer Packaged Goods industry, placing it in the top 43.1%.
Is Star Combo Pharma's Receivables Turnover too high?
Star Combo Pharma's current Receivables Turnover is 5.11. The Consumer Packaged Goods industry median Receivables Turnover is 9.35. Star Combo Pharma's value of 5.11 is 45.3% below this industry median. Based on the distribution chart, Star Combo Pharma ranks #837 out of 1944 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Star Combo Pharma has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's Receivables Turnover compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Star Combo Pharma ranks #837 out of 1944 companies for Receivables Turnover. This puts Star Combo Pharma in the upper half of its industry. The industry median Receivables Turnover is 9.35. Star Combo Pharma's value of 5.11 is 45.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Consumer Packaged Goods company?
The median Receivables Turnover among Consumer Packaged Goods companies is 9.35, based on 1,944 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Combo Pharma's current Receivables Turnover of 5.11 is 45.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Star Combo Pharma and its competitors. For the Consumer Packaged Goods industry, the median Receivables Turnover is 9.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Combo Pharma's current Receivables Turnover is 5.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.13 — trading right at its estimated fair value. The current Receivables Turnover is 5.11 and 45.3% below the Consumer Packaged Goods industry median of 9.35. Star Combo Pharma's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current Receivables Turnover is 5.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Combo Pharma (ASX:S66) Overvalued in 2026?
Based on GuruFocus' analysis, Star Combo Pharma stock appears to be undervalued.
The current stock price of A$0.13 is trading 0% below its estimated GF Value™ of A$0.13.
GuruFocus considers Star Combo Pharma to be Fairly Valued.
Key valuation signals for ASX:S66:
Receivables Turnover: 5.11
GF Value™: A$0.13 vs. price of A$0.13 (0% below fair value)
Industry Position: 45.3% below the Consumer Packaged Goods median (#837 of 1944)
No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
35GF Score
Get the complete analysis for ASX:S66
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:S66 has been successfully added to your 
